Evidence map›Paper›PMID 31231122›Full record

ArticleBritish journal of cancer2019

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.

Daniel Morgensztern, Michal Rose, Saiama N Waqar, John Morris, Patrick C Ma, Thomas Reid, Christina E Brzezniak, Karen G Zeman, Arvinda Padmanabhan, JoAnn Hirth and 3 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02489903 (A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens), which is not on this map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02489903 phase2completednot on this map

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

TypeinterventionalSponsorEpicentRx, Inc.Ran2015 to 2021Enrolled139ConditionsSmall Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial CancerArmsRRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan
3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Daniel MorgenszternWashington University School of Medicine, St. Louis, MO, USA. danielmorgensztern@wustl.edu.
Michal RoseVA Connecticut, West Haven, CT, USA.
Saiama N WaqarWashington University School of Medicine, St. Louis, MO, USA.
John MorrisUniversity of Cincinnati Cancer Institute, Cincinnati, OH, USA.
Patrick C MaWest Virginia University, Morgantown, WV, USA.
Thomas ReidMemorial Hospital, South Bend, IN, USA.
Christina E BrzezniakWalter Reed National Military Medical Center, Bethesda, MD, USA.
Karen G ZemanWalter Reed National Military Medical Center, Bethesda, MD, USA.
Arvinda PadmanabhanBaptist Health, Lexington, KY, USA.
JoAnn HirthHenry Ford Allegiance Health, Jackson, MI, USA.
Alexander I SpiraVirginia Cancer Specialists, Fairfax, VA, USA.
Jane B TrepelNational Cancer Institute, Bethesda, MD, USA.
Sukhmani K PaddaStanford University School of Medicine, Stanford, CA, USA.

Funding

Signal Transduction Events and the Regulation of Cell GrowthZICSC006743 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI TREPEL, JANE B · 2009 to 2023
$13.8M
6 · The paper itself

Abstract

backgroundThis exploratory single-arm phase II study evaluated the efficacy and safety of RRx-001 followed by reintroduction of platinum plus etoposide in patients with previously treated small-cell lung cancer (SCLC).

methodsPatients were treated with RRx-001 4 mg IV on day 1 of each week of a 21-day cycle followed at progression by re-challenge with etoposide 80-100 IV mg/m

resultsTwenty-six patients were enroled and received at least one dose of RRx-001. The median number of prior lines of therapy was 2 (range 1-9) and 19 (73.1%) patients had platinum-resistant disease. In the intention-to-treat population, one patient (3.8%) had complete response and six (23.1%) had partial response on platinum plus etoposide. The estimated median and 12-month OS from enrolment were 8.6 months and 44.1%, respectively. The most common treatment-emergent adverse event from RRx-001 was mild discomfort at the infusion site (23%).

conclusionsRRx-001 followed by re-challenge with platinum plus etoposide chemotherapy is feasible and associated with promising results. CLINICAL

trial registrationNCT02489903.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAzetidinesCarboplatinCisplatinEtoposideFemaleHumansLung NeoplasmsMaleMiddle AgedNitro CompoundsSmall Cell Lung CarcinomaAzetidinesCarboplatinCisplatinEtoposideNitro CompoundsRRx-001

Identifiers

PMID31231122
PMCPMC6738071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.